UY32190A - Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales - Google Patents

Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales

Info

Publication number
UY32190A
UY32190A UY0001032190A UY32190A UY32190A UY 32190 A UY32190 A UY 32190A UY 0001032190 A UY0001032190 A UY 0001032190A UY 32190 A UY32190 A UY 32190A UY 32190 A UY32190 A UY 32190A
Authority
UY
Uruguay
Prior art keywords
derivatives
anilina
sulfoximine
cdk
inhibitors
Prior art date
Application number
UY0001032190A
Other languages
English (en)
Inventor
Lienau Philip
Dr Rolf Jautelat
Dr Ulrich Luecking
Dr Gerhard Siemeister
Schulze Julia
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32190A publication Critical patent/UY32190A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de anilina-pirimidina sustituidos con sulfoximina de la Fórmula (I) métodos de producción de los mismos y su uso medicación para el tratamiento de diversas enfermedades.
UY0001032190A 2008-10-21 2009-10-20 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales UY32190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (de) 2008-10-21 2008-10-21 Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
UY32190A true UY32190A (es) 2010-05-31

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032190A UY32190A (es) 2008-10-21 2009-10-20 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales

Country Status (38)

Country Link
US (1) US8735412B2 (es)
EP (2) EP2179991A1 (es)
JP (1) JP5564054B2 (es)
KR (1) KR20110069115A (es)
CN (1) CN102197029B (es)
AR (1) AR074053A1 (es)
AU (1) AU2009306733C1 (es)
BR (1) BRPI0920112A2 (es)
CA (1) CA2739739C (es)
CO (1) CO6361926A2 (es)
CR (1) CR20110210A (es)
CU (1) CU24052B1 (es)
CY (1) CY1115590T1 (es)
DK (1) DK2350026T3 (es)
DO (1) DOP2011000107A (es)
EA (1) EA019230B1 (es)
EC (1) ECSP11010992A (es)
ES (1) ES2499028T3 (es)
HN (1) HN2011001019A (es)
HR (1) HRP20140830T1 (es)
IL (1) IL211713A (es)
MA (1) MA32723B1 (es)
MX (1) MX2011004238A (es)
MY (1) MY155230A (es)
NZ (1) NZ592314A (es)
PA (1) PA8846201A1 (es)
PE (1) PE20110546A1 (es)
PL (1) PL2350026T3 (es)
PT (1) PT2350026E (es)
RS (1) RS53523B1 (es)
SA (1) SA109300632B1 (es)
SI (1) SI2350026T1 (es)
TN (1) TN2011000199A1 (es)
TW (2) TWI458716B (es)
UA (1) UA103500C2 (es)
UY (1) UY32190A (es)
WO (1) WO2010046035A1 (es)
ZA (1) ZA201103727B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
DE102011080991A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
CN103930399B (zh) 2011-09-16 2016-03-16 拜耳知识产权有限责任公司 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
AU2013234451A1 (en) * 2012-03-21 2014-09-25 Bayer Intellectual Property Gmbh Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
US9884849B2 (en) * 2014-10-16 2018-02-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
WO2020055758A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
AU744986B2 (en) 1997-07-12 2002-03-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Cdk-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
WO2003076437A1 (de) 2002-03-11 2003-09-18 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
US7504410B2 (en) 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP1794134A1 (de) * 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CN102197029A (zh) 2011-09-21
EP2350026B1 (de) 2014-06-18
US20110294838A1 (en) 2011-12-01
CU20110088A7 (es) 2011-12-28
DOP2011000107A (es) 2011-05-15
MA32723B1 (fr) 2011-10-02
JP5564054B2 (ja) 2014-07-30
IL211713A0 (en) 2011-06-30
HRP20140830T1 (hr) 2014-11-21
WO2010046035A1 (de) 2010-04-29
CN102197029B (zh) 2014-05-14
EP2350026A1 (de) 2011-08-03
HN2011001019A (es) 2013-07-01
NZ592314A (en) 2013-02-22
PA8846201A1 (es) 2010-05-26
MX2011004238A (es) 2011-05-23
ECSP11010992A (es) 2011-05-31
TWI458716B (zh) 2014-11-01
ZA201103727B (en) 2014-11-26
CU24052B1 (es) 2014-12-26
IL211713A (en) 2015-04-30
RS53523B1 (en) 2015-02-27
SA109300632B1 (ar) 2013-07-04
MY155230A (en) 2015-09-30
AU2009306733A1 (en) 2010-04-29
JP2012506391A (ja) 2012-03-15
AR074053A1 (es) 2010-12-22
EP2179991A1 (de) 2010-04-28
AU2009306733B2 (en) 2015-11-12
KR20110069115A (ko) 2011-06-22
PT2350026E (pt) 2014-09-12
PL2350026T3 (pl) 2014-11-28
EA019230B1 (ru) 2014-02-28
CA2739739C (en) 2016-12-20
CR20110210A (es) 2011-06-08
TW201020237A (en) 2010-06-01
TN2011000199A1 (en) 2012-12-17
EA201100623A1 (ru) 2011-12-30
SI2350026T1 (sl) 2014-10-30
CY1115590T1 (el) 2017-01-04
PE20110546A1 (es) 2011-08-12
BRPI0920112A2 (pt) 2015-12-22
DK2350026T3 (da) 2014-09-15
ES2499028T3 (es) 2014-09-26
US8735412B2 (en) 2014-05-27
CA2739739A1 (en) 2010-04-29
TW201444803A (zh) 2014-12-01
AU2009306733C1 (en) 2016-07-14
TWI496774B (zh) 2015-08-21
UA103500C2 (uk) 2013-10-25
CO6361926A2 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
UY32190A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
UY31277A1 (es) Nuevos derivados de 6-triazolopiridacina -sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmacéuticas y nueva utilizacion principalmente como inhibidores de met
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180919